The U.S. Food and Drug Administration has approved a generic form of Copaxone® (glatiramer acetate), called Glatopa™ (Sandoz, a Novartis company, developed with Momenta) as a disease-modifying therapy for people with relapsing forms of MS, including those who have experienced a first clinical episode and have MRI features consistent with MS. The generic medication is a 20mg dose injected subcutaneously daily. This approval means that the manufacturer provided evidence that this generic medication is equivalent to the brand-name drug (Copaxone®). There is no information yet on when Glatopa will be available by prescription in the United States or its cost.
CMSC Disclaimer The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.